A feasibility study of functional preservation in craniospinal irradiation with photon for pediatric medulloblastoma
Journal of Applied Clinical Medical Physics · 2026
DOI: 10.1002/acm2.70474 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Applied Clinical Medical Physics, 2026. Verfasst von Keqiang Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Medulloblastoma, Craniospinal Irradiation, Radiotherapy Planning, Computer-Assisted, Organs at Risk. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Craniospinal irradiation (CSI) is essential for treating pediatric medulloblastoma (MB) but causes significant long‐term toxicities. Existing dose‐reduction or partial‐sparing strategies improve neurocognitive outcomes but may compromise survival or fail to address other late effects.
Methods
A new functional preservation CSI (FP‐CSI) technique was developed to spare the hippocampus, hypothalamic‐pituitary axis (HPA), cochlea, and scalp while ensuring homogeneous vertebral coverage. Eight pediatric patients with average‐risk MB were retrospectively planned with volumetric modulated arc therapy (VMAT) using both FP‐CSI and standard CSI (S‐CSI). Dosimetric parameters for the planning target volume (PTV) and organs at risk (OARs), radiobiological effects, plan robustness, plan complexity, and plan quality assurance (QA) were compared.
Results
FP‐CSI significantly reduced mean doses to the hippocampus (12.4 vs. 23.9 Gy), hypothalamus (14.7 vs. 23.9 Gy), and pituitary gland (15.4 vs. 24.1 Gy, all p < 0.01). Vertebral dose gradients were halved (4.7 vs. 8.7 Gy). Moderate dose reductions were also achieved for the cochlea and scalp. Compared with S‐CSI, FP‐CSI exhibited slightly inferior PTV homogeneity (HI: 0.16 vs. 0.07) and conformity (CI: 0.88 vs. 0.93), but coverage remained clinically acceptable. Normal tissue complication probability (NTCP) modeling showed pronounced decreases in predicted neurocognitive and endocrine toxicity risks, with probability of neurocognitive impairment reduced from 84.5% to 24.9% and probability of endocrine dysfunction from 44.7% to 27.3%. FP‐CSI increased modulation complexity and produced slightly lower gamma passing rates for cranial beams, while spinal beam deliverability remained similar to S‐CSI. Robustness analysis indicated greater sensitivity of FP‐CSI to setup and rotational errors. Nevertheless, 3D dose reconstruction confirmed accurate delivery, with volumetric dose deviations generally below 1 Gy.
Conclusion
FP‐CSI effectively spares critical functional structures while maintaining clinically acceptable target coverage, and offers a promising strategy to reduce long‐term radiotherapy‐induced toxicities in pediatric MB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Tianjin Medical University General Hospital, Tianjin, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, K., Chen, J., Jian, J., Wang, P., Zhang, H., & Zhang, W. (2026). A feasibility study of functional preservation in craniospinal irradiation with photon for pediatric medulloblastoma. Journal of Applied Clinical Medical Physics. https://doi.org/10.1002/acm2.70474
Vancouver
Wang K, Chen J, Jian J, Wang P, Zhang H, Zhang W. A feasibility study of functional preservation in craniospinal irradiation with photon for pediatric medulloblastoma. Journal of Applied Clinical Medical Physics. 2026. doi:10.1002/acm2.70474
BibTeX
@article{Wang2026,
author = {Wang, Keqiang and Chen, Jie and Jian, Jianbo and Wang, Peng and Zhang, Hongyang and Zhang, Wenxue},
title = {A feasibility study of functional preservation in craniospinal irradiation with photon for pediatric medulloblastoma},
journal = {Journal of Applied Clinical Medical Physics},
year = {2026},
doi = {10.1002/acm2.70474}
}
EUVIMED